Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En 6-månaders och 18-månaders randomiserad dubbelstudie som utvärderar säkerhet och effekt av Buntanetap hos deltagare med tidig AD (DUET-AD)

16 november 2026 uppdaterad av: Annovis Bio Inc.

En 6-månaders och 18-månaders prospektiv, randomiserad, placebokontrollerad, dubbelblind dubbel klinisk prövning som undersöker effektivitet och säkerhet för Buntanetap vid behandling av deltagare av tidig Alzheimers sjukdom

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

  • Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
  • Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
  • What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.

Participants will:

  • Take buntanetap/Posiphen or a placebo every day for 18 months
  • Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
  • Complete pre- and post-clinic visit phone calls

Studieöversikt

Status

Aktiv, inte rekryterande

Studietyp

Interventionell

Inskrivning (Faktisk)

861

Fas

  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Chandler, Arizona, Förenta staterna, 85286
        • MD First Research
      • Phoenix, Arizona, Förenta staterna, 85004
        • Xenoscience
      • Scottsdale, Arizona, Förenta staterna, 85258
        • Clinical Endpoints
    • California
      • Anaheim, California, Förenta staterna, 92805
        • Advanced Research Center
      • Canoga Park, California, Förenta staterna, 91303
        • Hope Clinical Research
      • Imperial, California, Förenta staterna, 92251
        • Sun Valley Research
      • Los Angeles, California, Förenta staterna, 90095
        • Mary S. Easton Center for Alzheimer's Research and Care, UCLA
      • Sacramento, California, Förenta staterna, 95816
        • UC Davis Alzheimer's Disease Research Center
      • San Marcos, California, Förenta staterna, 92069
        • The Neuron Clinic
    • Colorado
      • Basalt, Colorado, Förenta staterna, 81621
        • Mountain Neurological Center
      • Englewood, Colorado, Förenta staterna, 80113
        • CenExel Rocky Mountain
    • Connecticut
      • Norwalk, Connecticut, Förenta staterna, 06851
        • Research Center for Clinical Trials
    • Florida
      • Aventura, Florida, Förenta staterna, 33180
        • Visionary Investigators Network
      • Boca Raton, Florida, Förenta staterna, 33487
        • SFM Clinical Research
      • Clermont, Florida, Förenta staterna, 34711
        • K2 Medical Research
      • Daytona Beach, Florida, Förenta staterna, 32114
        • K2 Medical Research Daytona
      • Fort Myers, Florida, Förenta staterna, 33912
        • Neuropsychiatric Research Center
      • Hallandale, Florida, Förenta staterna, 33009
        • Velocity Clinical
      • Jacksonville, Florida, Förenta staterna, 32216
        • Jacksonville Center for Clinical Research
      • Lady Lake, Florida, Förenta staterna, 32159
        • K2 Medical Research
      • Lake Worth, Florida, Förenta staterna, 33462
        • Headlands Research JEM
      • Lakeland, Florida, Förenta staterna, 33803
        • Accel Research Sites Lakeland (Alcanza)
      • Maitland, Florida, Förenta staterna, 32751
        • K2 Medical Research
      • Melbourne, Florida, Förenta staterna, 32940
        • ClinCloud Clinical Research
      • Merritt Island, Florida, Förenta staterna, 32952
        • Flourish Research/Merritt Island Medical Research
      • Miami, Florida, Förenta staterna, 33137
        • Miami Jewish Health
      • Naples, Florida, Förenta staterna, 34102
        • Aqualane Clinical Research
      • New Port Richey, Florida, Förenta staterna, 34652
        • Suncoast Clinical Research
      • Orlando, Florida, Förenta staterna, 32832
        • Conquest Research
      • Tampa, Florida, Förenta staterna, 33609
        • Axiom Brain Health, LLC
      • Winter Park, Florida, Förenta staterna, 32789
        • Conquest Research
    • Georgia
      • Decatur, Georgia, Förenta staterna, 30030
        • Accel Neurosciences
      • Gainesville, Georgia, Förenta staterna, 30501
        • CARE (Center for Advanced Research & Education)
    • Hawaii
      • Honolulu, Hawaii, Förenta staterna, 96817
        • Hawaii Pacific Neuroscience
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60612
        • Rush University Medical Center
      • Chicago, Illinois, Förenta staterna, 60611
        • Re:Cognition Chicago
      • Chicago, Illinois, Förenta staterna, 60618
        • Charter Research Chicago
      • Chicago, Illinois, Förenta staterna, 60640
        • Great Lakes Clinical Trials/Flourish Research
      • Springfield, Illinois, Förenta staterna, 62702
        • Southern Illinois University
    • Indiana
      • Indianaopolis, Indiana, Förenta staterna, 46256
        • JWM Research
    • Kansas
      • Wichita, Kansas, Förenta staterna, 37214
        • Ascension via Christi Research
    • Louisiana
      • Metairie, Louisiana, Förenta staterna, 70006
        • Tandem Intermediate
    • Maryland
      • Pikesville, Maryland, Förenta staterna, 21208
        • Headlands Research Pharmasite
    • Massachusetts
      • Foxborough, Massachusetts, Förenta staterna, 02035
        • Neurology Center of New England, PC
      • Plymouth, Massachusetts, Förenta staterna, 02360
        • Headlands Research Easter Massachusetts
      • Russells Mills, Massachusetts, Förenta staterna, 02747
        • Mayflower Clinical
      • Springfield, Massachusetts, Förenta staterna, 01103
        • Elixia MA
    • Michigan
      • Farmington Hills, Michigan, Förenta staterna, 48334
        • Quest Research Institute
    • Mississippi
      • Flowood, Mississippi, Förenta staterna, 39232
        • Precise Research Center
    • Missouri
      • Chesterfield, Missouri, Förenta staterna, 63005
        • Clinical Research Professionals - Headlands Research
    • Nevada
      • Las Vegas, Nevada, Förenta staterna, 89121
        • Oasis Clinical Trials LLC
    • New Jersey
      • Toms River, New Jersey, Förenta staterna, 08755
        • Cenexel Advanced Medical Research of New Jersey (AMRI)
      • West Long Branch, New Jersey, Förenta staterna, 07764
        • Advanced Clinical Institute
    • New York
      • Amherst, New York, Förenta staterna, 14226
        • Dent Neurologic Institute
      • Brooklyn, New York, Förenta staterna, 11235
        • SPRI
      • Lake Success, New York, Förenta staterna, 11042
        • Neurological Associates of Long Island
      • New York, New York, Förenta staterna, 10003
        • New York Neurology Associates
      • Staten Island, New York, Förenta staterna, 10314
        • Richmond Behavioral Associates
      • Syracuse, New York, Förenta staterna, 13210
        • Ichor Research
    • North Carolina
      • Durham, North Carolina, Förenta staterna, 27705
        • Duke University
      • Matthews, North Carolina, Förenta staterna, 28105
        • AMC Research/Flourish Research
    • Ohio
      • Beavercreek, Ohio, Förenta staterna, 45432
        • American Clinical Research Center
      • Centerville, Ohio, Förenta staterna, 45459
        • Valley Medical Research
      • Independence, Ohio, Förenta staterna, 44131
        • Insight Clinical Trials
    • Oregon
      • Portland, Oregon, Förenta staterna, 97210
        • Summit Headlands
    • Pennsylvania
      • Media, Pennsylvania, Förenta staterna, 19063
        • Suburban Research Associates
      • Plymouth Meeting, Pennsylvania, Förenta staterna, 19462
        • K2 Keystone
    • Rhode Island
      • East Providence, Rhode Island, Förenta staterna, 02914
        • Rhode Island Mood and Memory Research Institute
    • South Carolina
      • Summerville, South Carolina, Förenta staterna, 29486
        • Palmetto Primary Care & Specialty Physicians
    • Tennessee
      • Cordova, Tennessee, Förenta staterna, 38018
        • Neurology Clinic, P.C.
      • Nashville, Tennessee, Förenta staterna, 37204
        • K2 Medical Research Nashville
    • Texas
      • Austin, Texas, Förenta staterna, 78757
        • Senior Adults Specialty Research
      • Houston, Texas, Förenta staterna, 77094
        • NeuroMind Clinical Trials
      • Round Rock, Texas, Förenta staterna, 78681
        • Central Texas Neurology Associates
      • Wichita Falls, Texas, Förenta staterna, 76309
        • Grayline Research Center
    • Vermont
      • Bennington, Vermont, Förenta staterna, 05201
        • Memory Clinic, Inc.
    • Virginia
      • Arlington, Virginia, Förenta staterna, 22205
        • Sana Research
      • Fairfax, Virginia, Förenta staterna, 22031
        • Re:Cognition Fairfax

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

55 år till 85 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.

  2. Male or female, aged 55 - 85 years.

  3. MMSE 20-28 at screening and baseline.

  4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.

  5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.

  6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.

  7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.

  8. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    • Intrauterine device (IUD),

    • Intrauterine hormone-releasing system (IUS),

    • Bilateral tubal occlusion,

    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),

    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
  9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    • IUD,
    • IUS,
    • Bilateral tubal occlusion.
  10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.

  11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.

  12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.

    • Cholinesterase inhibitors and/or memantine medication,
    • Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
    • Mood-stabilizing psychotropic agents including, but not limited to, lithium.
  13. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.

Exclusion Criteria:

  1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.

  3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).

  5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.

  6. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

  7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.

  8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).

  9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.

  10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.

  13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  14. Participants with learning disability or developmental delay.

  15. Participants whom the PI deems to be otherwise ineligible.

  16. Participants with a known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified Microcrystalline Cellulose
    • Dibasic Calcium Phosphate Dihydrate
    • Mannitol
    • Stearic Acid
    • Hypromellosee (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  17. Participant is currently pregnant, breast-feeding, and/or lactating.

  18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.

  19. Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Placebo

Placebo capsule by mouth once daily for 18 months

Experimentell: buntanetap

30mg capsule by mouth once daily for 18 months

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Tidsram: From screening to 6-month readout, to end of treatment at 18 months.

ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment.

From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Tidsram: From screening to 6-month readout, to end of treatment at 18 months.

The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function.

From screening to 6-month readout, to end of treatment at 18 months.

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

4 februari 2025

Primärt slutförande (Beräknad)

1 december 2027

Avslutad studie (Beräknad)

1 juni 2028

Studieregistreringsdatum

Först inskickad

26 november 2024

Först inskickad som uppfyllde QC-kriterierna

26 november 2024

Första postat (Faktisk)

29 november 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

19 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 november 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera